Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Rifabutin on Fostemsavir +/- Ritonavir
NCT02138084Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Maximum observed plasma concentration of BMS-626529 and Area under the concentration-time curve in 1 dosing interval of BMS-626529. Started May 2014; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02138084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138084.